Generic Product News
Marketed by: Prasco Laboratories (Cininnati, OH)
Compare to: Vancocin HCl (ViroPharma Incorporated)
Indication: Prasco Laboratories announces it will market an authorized generic version of ViroPharma’s Vancocin HCl capsules, following a distribution and supply agreement between the 2 manufacturers. Vancomycin Hydrochloride Capsules are indicated for the treatment of Clostridium difficile—associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. The capsules must be given orally in both cases and are not effective for other types of infections. The generic will launch immediately.
Dosage Form: Capsules: 125 and 250 mg
For More Information: www.prasco.com
Mixed Amphetamine Salts ER Capsules
Marketed by: Actavis Group (Morristown, NJ)
Compare to: Adderall XR (Shire Pharmaceuticals)
Indication: Actavis Group has received FDA approval to market Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended-Release Capsules (Mixed Amphetamine Salts ER) CII, a generic equivalent of Adderall XR. It is indicated for the treatment of attention-deficit/hyperactivity disorder in children, adolescents, and adults, and will be manufactured in all medication strengths. Distribution of the generic has commenced.
Dosage Form: Capsules: 5, 10, 15, 20, 25, and 30 mg
For More Information: www.actavis.us
Marketed By: Mylan Pharmaceuticals Inc (Pittsburgh, PA)
Compare to: Clarinex (Schering, a subsidiary of Merck & Co)
Indication: Mylan Pharmaceuticals Inc has launched Desloratadine Tablets, a generic version of Schering’s Clarinex. The medication is an oral antihistamine for the treatment of nasal and nonnasal symptoms associated with seasonal and perennial allergic rhinitis. It is indicated for adults and children 12 years and older, and will be released only in 5-mg tablet form. Mylan announced that it is shipping the product immediately.
Dosage Form: Tablets: 5 mg
For More Information: www.mylan.com
Methylphenidate Hydrochloride Extended-Release Capsules
Marketed By: Teva Pharmaceuticals (North Wales, PA)
Compare to: Ritalin LA (Novartis)
Indication:Teva Pharmaceuticals announces the introduction of Methylphenidate Hydrochloride Extended-Release Capsules, an AB-rated bioequivalent to Novartis’ Ritalin LA. It is indicated for controlling the symptoms of attentiondeficit/hyperactivity disorder in adults and children. The medication will be available in 20-, 30-, and 40-mg strengths in bottles of 100. Each capsule will contain both immediate-release and delayed-released pellets and should be taken once daily in the morning, either by swallowing the capsules whole or sprinkling the contents on applesauce.
Dosage Form: Capsules: 20, 30, and 40 mg
For More Information: www.tevausa.com